



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

15 May 2023
EMA/CAT/184641/2023
Human Medicines Division

Committee for Advanced Therapies (CAT)

Minutes of the meeting on 19-21 April 2023

Chair: Ilona Reischl; Vice-Chair: Carla Herberts

Disclaimers

Some of the information contained in these minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, these minutes are a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).



Table of contents

1.	Introduction	5
1.1.	Welcome and declarations of interest of members, alternates and experts.....	5
1.2.	Adoption of agenda	5
1.3.	Adoption of the minutes	5
2.	Evaluation of ATMPs	5
2.1.	Opinions	5
2.2.	Oral explanations	5
2.2.1.	Lenadogene nolparvovec - Orphan - EMEA/H/C/005047	5
2.3.	Day 180 list of outstanding issues	6
2.4.	Day 120 list of questions	6
2.5.	Day 80 assessment reports	6
2.5.1.	Exagamglogene autotemcel - PRIME - Orphan - EMEA/H/C/005763	6
2.6.	Update on ongoing initial applications.....	6
2.7.	New applications	7
2.8.	Withdrawal of initial marketing authorisation application	7
2.9.	Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004	7
2.10.	Companion diagnostics.....	7
2.10.1.	Initial consultation	7
2.10.2.	Follow-up consultation.....	7
2.11.	Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008	7
2.11.1.	Abecma - idecabtagene vicleucel - Orphan - EMEA/H/C/004662/II/0027	7
2.11.2.	Alofisel - darvadstrocel - Orphan - EMEA/H/C/004258/II/0045/G.....	8
2.11.3.	Imlygic - talimogene laherparepvec - EMEA/H/C/002771/II/0059	8
2.11.4.	ROCTAVIAN - valoctocogene roxaparvovec - Orphan - EMEA/H/C/005830/II/0004/G	8
2.11.5.	Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0003	8
2.11.6.	Abecma – idecabtagene vicleucel – Orphan - EMEA/H/C/PSUSA/00010954/202209	9
2.12.	Extension applications.....	9
2.13.	Other Post-Authorisation Activities	9
2.13.1.	Abecma - idecabtagene vicleucel - Orphan - EMEA/H/C/004662/R/0029	9
2.13.2.	CARVYKTI - ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095/MEA/007.1.....	9
2.13.3.	Ebvallo - tabelecleucel - Orphan - EMEA/H/C/004577/REC/006	10
2.13.4.	ROCTAVIAN - valoctocogene roxaparvovec - Orphan - EMEA/H/C/005830/R/0003.....	10
2.14.	GMP and GCP inspections requests.....	10

3.	Certification of ATMPs	10
3.1.	Opinion.....	11
3.2.	Day 60 Evaluation Reports.....	11
3.3.	New Applications.....	11
4.	Scientific Recommendation on Classification of ATMPs	11
4.1.	New requests – Appointment of CAT Coordinator	11
4.1.1.	Living human adult allogeneic immunomodulatory progenitor (iMP) cells	11
4.1.2.	Allogeneic viable natural killer (NK) cells CD56+ CD3-	11
4.1.3.	Recombinant Adeno-associated virus serotype 9 vector containing the human-lysosome-associated membrane glycoprotein 2 isoform B transgene	11
4.2.	Day 30 ATMP scientific recommendation	12
4.2.1.	Ixoberogene soroparvovec (genetically engineered, replication-incompetent adeno-associated virus vector comprising the AAV.7m8 capsid proteins, carrying a version of complementary deoxyribonucleic acid for aflibercept)	12
4.2.2.	Ex vivo fused allogeneic human myoblasts (MB-N) with autologous human myoblast (MB-ALS)	12
4.2.3.	Ex vivo fused allogeneic human myoblasts (MB-N) with autologous human bone marrow derived mesenchymal stem cells (MSC-ALS)	12
4.2.4.	Ex vivo fused allogeneic human mesenchymal stem cell (MSC-N) with autologous human myoblast (MB-ALS).....	12
4.2.5.	Ex vivo fused allogeneic human myoblasts (MB-N1) with allogeneic human myoblasts (MB-N2)	13
4.2.6.	Helper-dependent adenovirus vector coding for interleukin-1 receptor antagonist.....	13
4.2.7.	Autologous CD34+ cells from mobilised peripheral blood	13
4.2.8.	Biotinylated cultured reticulocytes, cultured from haematopoietic stem cells	13
4.3.	Day 60 revised scientific recommendation (following list of questions)	13
4.3.1.	Autologous chondrocytes cultured in hyaluronan-derived scaffold	13
4.4.	Finalisation of procedure	14
4.4.1.	Lyophilised supernatant of a pathogen inactivated and gamma sterilised platelet lysate ...	14
4.4.2.	Autologous intestinal organoid derived from adult stem cells from intestinal epithelial tissue	14
4.5.	Follow-up and guidance	14
5.	Scientific Advice	14
5.1.	New requests - appointment of CAT Rapporteurs	14
5.1.1.	Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers	14
5.1.2.	Scientific advice procedures starting at the next SAWP meeting	15
5.2.	Procedures discussed at SAWP – 1st reports, D40 JRs, LoIs	15
5.3.	Finalisation of D70 procedures – feedback from the discussion meeting	15
5.4.	Final Advice Letters for procedures finalised the previous month	15

6.	Pre-Authorisation Activities	15
6.1.	Paediatric investigation plans	15
6.2.	ITF briefing meetings in the field of ATMPs	15
6.3.	Priority Medicines (PRIME) – Eligibility requests	15
6.3.1.	Month 0 - Start of the procedure	15
6.3.2.	Month 1 – Discussion of eligibility	15
6.3.3.	Month 2 – Recommendation of eligibility	16
6.3.4.	Ongoing support	16
7.	Organisational, regulatory and methodological matters	16
7.1.	Mandate and organisation of the CAT	16
7.1.1.	CAT membership	16
7.1.2.	Vote by proxy	16
7.1.3.	CAT Strategic Review & Learning meeting (SRLM) under the Sweden presidency, 4 and 5 May 2023, Upsala (Sweden)	16
7.1.4.	New timeschedule layout	16
7.2.	Coordination with EMA Scientific Committees	16
7.3.	Coordination with EMA Working Parties/Working Groups/Drafting Groups	17
7.3.1.	PRIME implementation of 5-year review recommendations – 2023 pilot features and guidance updates	17
7.3.2.	Joint EU GCP inspectors-clinical assessors virtual workshop, 26 June 2023	17
7.3.3.	Re-organisation of Biologics Working Party (BWP)	17
7.4.	Cooperation with the EU regulatory network	17
7.5.	Cooperation with international regulators	17
7.5.1.	ATMP cluster teleconference with US-FDA, Health Canada and PMDA (Japan)	17
7.6.	CAT work plan	18
7.6.1.	Guideline of quality, non-clinical and clinical requirements for investigational ATMPs in clinical trials	18
7.7.	Planning and reporting	18
7.8.	Others	18
7.8.1.	CAT stakeholder meeting 2023	18
7.8.2.	Euroscan – International HealthTechScan (i-HTS)	18
7.8.3.	European Health and Digital Executive Agency (HaDEA)	19
8.	Any other business	19
8.1.	New Expert Management Tool	19
9.	List of participants	19
10.	Explanatory notes	23

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

The Chairperson opened the meeting by welcoming all participants. The meeting was held remotely.

In accordance with the Agency's policy on handling of declarations of interests of scientific committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and on the topics in the agenda of the current meeting, the Committee Secretariat announced that no restriction in the involvement of meeting participants for agenda topics was identified.

Participants were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared. Restrictions applicable to this meeting are captured in the List of participants included in the minutes.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure. All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. Adoption of agenda

The CAT agenda for 19-21 April 2023 meeting was adopted.

1.3. Adoption of the minutes

The CAT minutes for 22-23 March 2023 meeting were adopted with one amendment to agenda point 4.2.3.

2. Evaluation of ATMPs

2.1. Opinions

No items

2.2. Oral explanations

2.2.1. Lenadogene nolparvovec - Orphan - EMEA/H/C/005047

GenSight Biologics S.A.; Treatment of vision loss due to Leber hereditary optic neuropathy (LHON)

Scope: Oral explanation

Action: for discussion

List of outstanding issues adopted on 09.12.2022. List of questions adopted on 19.02.2021.

The Rapporteur highlighted the outstanding major objections (MO) .

After the preparatory discussion, the CAT chair welcomed a patient with LHON.

During the oral explanation, the applicant mainly focused on the clinical MO.

The patient, on questions from the CAT, provided his view of the description of the patient population and the clinical relevance of the effect claimed by the applicant.

In absence of the applicant and the patient, CAT discussed the outcome of the assessment of the responses to the list of outstanding issues and the additional information and justifications provided during the oral explanation. CAT agreed that the data are not sufficient for granting a marketing authorisation. A trend vote was taken, confirming that a majority of CAT members do not agree that a positive opinion can be adopted .

Post-meeting note: after debriefing, the applicant decided to withdraw the marketing authorisation application . The withdrawal letter and the withdrawal EPAR will be published on the EMA website.

2.3. Day 180 list of outstanding issues

No items

2.4. Day 120 list of questions

No items

2.5. Day 80 assessment reports

2.5.1. Exagamglogene autotemcel - PRIME - Orphan - EMEA/H/C/005763

Vertex Pharmaceuticals (Ireland) Limited; Treatment of transfusion-dependent β -thalassemia and sickle cell disease

Scope: Day 80 assessment report

Action: for information

The information was noted.

2.6. Update on ongoing initial applications

No items

2.7. New applications

2.8. Withdrawal of initial marketing authorisation application

No items

2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004

No items

2.10. Companion diagnostics

2.10.1. Initial consultation

2.10.1.1. In vitro diagnostic medical device - EMEA/H/D/006255

Indicated as an aid in the selection of adult haemophilia A patients for whom valoctocogene roxaparvec treatment is being considered

Scope: Request for supplementary information

Action: for adoption

The Rapporteur presented the assessment of suitability of the companion diagnostic (CDx) to screen patients to be treated with Roctavian.

It was clarified that the assessment of the performance of the assay is under the responsibility of the Notified Body; also, the wording of the intended use, e.g. "aid in the selection of ..." which is well described as part of the 'Instructions for Use (IfU)' document, is in line with the standard wording approved by FDA, and outside of the remit of this procedure.

CAT discussed the request for supplementary information (RSI): one additional question was included. The RSI was adopted.

2.10.2. Follow-up consultation

No items

2.11. Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

2.11.1. Abecma - idecabtagene vicleucel - Orphan - EMEA/H/C/004662/II/0027

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Rune Kjeklen

Scope: Quality, Opinion

Action: for adoption

Request for supplementary information adopted on 24.03.2023.

The opinion was adopted.

2.11.2. Alofisel - darvadstrocel - Orphan - EMEA/H/C/004258/II/0045/G

Takeda Pharma A/S

Rapporteur: Lisbeth Barkholt

Scope: Quality, Opinion

Action: for adoption

The opinion was adopted.

2.11.3. Imlygic - talimogene laherparepvec - EMEA/H/C/002771/II/0059

Amgen Europe B.V.

Rapporteur: Maija Tarkkanen

PRAC Rapporteur: Gabriele Maurer

Scope: Pharmacovigilance, Opinion (PRAC procedure)

Submission of an updated RMP version 10 in order to update and reclassify identified risk of 'disseminated herpetic infection' based on the cumulative assessment of literature review, and MAH Global Safety Database, and to remove studies 20180062 and 20180099 from Planned and Ongoing Studies from the list of Pharmacovigilance Plan studies in Annex II.

Action: for adoption

Request for supplementary information adopted on 20.01.2023.

The opinion was adopted.

2.11.4. ROCTAVIAN - valoctocogene roxaparvovec - Orphan - EMEA/H/C/005830/II/0004/G

BioMarin International Limited

Rapporteur: Violaine Closson Carella

Scope: Quality, Opinion

Action: for adoption

The opinion was adopted.

2.11.5. Breyanzi - lisocabtagene maraleucl / lisocabtagene maraleucl - EMEA/H/C/004731/II/0003

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Concetta Quintarelli

Scope: Quality, Clock stop extension

Action: for adoption

The clock stop extension was agreed.

2.11.6. Abecma – idecabtagene vicleucel – Orphan - EMEA/H/C/PSUSA/00010954/202209

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Rune Kjekken, PRAC Rapporteur: Ulla Wändel Liminga

Scope: variation following PSUR assessment: update of section 4.4 of the SmPC to add warning information on Parkinsonism and to mention it in the footnotes of the table in section 4.8 of the SmPC for the SOC "Nervous system disorders" (PRAC led procedure)

Action: for information

CAT noted the outcome of the PRAC-led variation to add information on Parkinsonism in the SmPC. The wording is aligned to that included in the SmPC for Carvykti.

2.12. Extension applications

No items

2.13. Other Post-Authorisation Activities

2.13.1. Abecma - idecabtagene vicleucel - Orphan - EMEA/H/C/004662/R/0029

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Rune Kjekken, Co-Rapporteur: Heli Suila, PRAC Rapporteur: Ulla Wändel Liminga
Scope: 1 year Renewal of Marketing Authorisation, Opinion

Action: for adoption

The Rapporteur presented the assessment of the second 1-year renewal for Abecma. CAT adopted the 1-year renewal of the marketing authorisation.

2.13.2. CARVYKTI - ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095/MEA/007.1

Janssen-Cilag International NV

Rapporteur: Jan Mueller-Berghaus
Scope: Pharmacovigilance, Follow up MEA

Revised protocol of study No PCSONCA0014: Survey to evaluate the effectiveness of the ciltacabtagene autoleucel HCP Educational Program and the Product Handling Training.

The MAH is requested to consider a stratified randomisation approach in order to ensure that the acceptable number in each category of HCPs will complete the survey. A minimum number of participants should be proposed for physicians, nurses, pharmacists and wards on the one hand, and also for HCPs involved in prescribing vs handling of ciltacabtagene

autoleucel in the selected countries. The estimations of effectiveness should also be performed separately, at least for HCPs involved in prescription, patient management and product handling in order to be able to interpret effectiveness in a meaningful way, as criteria for success and even the weighting of the questions is different. [From Initial MAA]

Action: for adoption

The outcome of the assessment was adopted.

2.13.3. Ebvallo - tabelecleucel - Orphan - EMEA/H/C/004577/REC/006

Pierre Fabre Medicament

Rapporteur: Egbert Flory

Scope: Quality, Opinion

Action: for adoption

The outcome of the assessment was adopted.

2.13.4. ROCTAVIAN - valoctocogene roxaparvovec - Orphan - EMEA/H/C/005830/R/0003

BioMarin International Limited

Rapporteur: Violaine Closson Carella, Co-Rapporteur: Silke Dorner, PRAC Rapporteur: Menno van der Elst

Scope: 1 year Renewal of Marketing Authorisation, Request for supplementary information

Action: for adoption

The Rapporteur presented the assessment of the first 1-year renewal for Roctavian. Some questions for clarification were raised. CAT adopted the request for supplementary information.

2.14. GMP and GCP inspections requests

No items

3. Certification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Opinion

3.2. Day 60 Evaluation Reports

3.3. New Applications

No items

4. Scientific Recommendation on Classification of ATMPs

Timetable:

-Start of the procedure:	21.04.2023
-EMA Coordinator's draft report:	02.05.2023
-CAT Coordinator's comments:	05.05.2023
-Revised scientific recommendation:	10.05.2023
-CAT's discussion of scientific recommendation:	17.05.2023

4.1. New requests – Appointment of CAT Coordinator

4.1.1. Living human adult allogeneic immunomodulatory progenitor (iMP) cells

Treatment of myocardial scarring

Scope: Appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed.

4.1.2. Allogeneic viable natural killer (NK) cells CD56+ CD3-

Treatment of patients with acute myeloid leukaemia (AML) who are in morphologic complete remission (CR) and for whom allogeneic haematopoietic stem cell transplantation (allo-HSCT) is not a suitable or preferred option

Scope: Appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed.

4.1.3. Recombinant Adeno-associated virus serotype 9 vector containing the human-lysosome-associated membrane glycoprotein 2 isoform B transgene

Treatment of Danon disease

Scope: Appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed.

4.2. Day 30 ATMP scientific recommendation

4.2.1. Ixoberogene soroparvovec (genetically engineered, replication-incompetent adeno-associated virus vector comprising the AAV.7m8 capsid proteins, carrying a version of complementary deoxyribonucleic acid for aflibercept)

Treatment of neovascular (wet) age-related macular degeneration

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 05.05.2023.

4.2.2. Ex vivo fused allogeneic human myoblasts (MB-N) with autologous human myoblast (MB-ALS)

Treatment of amyotrophic lateral sclerosis (ALS)

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 05.05.2023.

4.2.3. Ex vivo fused allogeneic human myoblasts (MB-N) with autologous human bone marrow derived mesenchymal stem cells (MSC-ALS)

Treatment of amyotrophic lateral sclerosis (ALS)

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 05.05.2023.

4.2.4. Ex vivo fused allogeneic human mesenchymal stem cell (MSC-N) with autologous human myoblast (MB-ALS)

Treatment of amyotrophic lateral sclerosis (ALS)

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 05.05.2023.

4.2.5. [Ex vivo fused allogeneic human myoblasts \(MB-N1\) with allogeneic human myoblasts \(MB-N2\)](#)

Treatment of amyotrophic lateral sclerosis (ALS)

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 05.05.2023.

4.2.6. [Helper-dependent adenovirus vector coding for interleukin-1 receptor antagonist](#)

Treatment of osteoarthritis of the knee

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 05.05.2023.

4.2.7. [Autologous CD34+ cells from mobilised peripheral blood](#)

Treatment of amyotrophic lateral sclerosis (ALS)

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 05.05.2023.

4.2.8. [Biotinylated cultured reticulocytes, cultured from haematopoietic stem cells](#)

Treatment of red cell supplementation (e.g. trauma/anaemia)

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 05.05.2023.

4.3. **Day 60 revised scientific recommendation (following list of questions)**

4.3.1. [Autologous chondrocytes cultured in hyaluronan-derived scaffold](#)

Repair of cartilage defects

Scope: ATMP scientific recommendation

Action: for discussion

CAT discussed the updated classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 05.05.2023.

4.4. Finalisation of procedure

4.4.1. Lyophilised supernatant of a pathogen inactivated and gamma sterilised platelet lysate

Treatment of topical treatment of skin ulcers

Scope: European Commission raised no comments. ATMP scientific recommendation

Action: for adoption

The classification report was adopted. The product does not fulfil the definition of an advanced therapy medicinal product as provided in Article 2(1) of Regulation (EC) No 1394/2007.

4.4.2. Autologous intestinal organoid derived from adult stem cells from intestinal epithelial tissue

Treatment of intractable ulcer

Scope: European Commission raised no comments. ATMP scientific recommendation

Action: for adoption

The classification report was adopted. The product does fulfil the definition of a tissue engineered product as provided in Article 2(1) of Regulation (EC) No 1394/2007.

4.5. Follow-up and guidance

No items

5. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. New requests - appointment of CAT Rapporteurs

5.1.1. Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers

Timetable:

- Start of procedure at SAWP:	11-14.04.2023
- Appointment of CAT Peer Reviewers:	19-21.04.2023
- SAWP first reports:	02.05.2023
- CAT Peer Reviewer comments (NC/C)	05.05.2023
- CAT Peer Reviewer comments (Q)	10.05.2023
- Discussion at SAWP:	08-10.2023

- Discussion at CAT and feedback to SAWP: 15-17.05.2023

5.1.2. Scientific advice procedures starting at the next SAWP meeting

Timetable:

- Start of procedure at SAWP:	13-16.03.2023
- Appointment of CAT Peer Reviewers:	22-24.03.2023
- SAWP first reports:	03.04.2023
- CAT Peer Reviewer comments (NC/C):	05.04.2023
- CAT Peer Reviewer comments (Q):	12.04.2023
- Discussion at SAWP:	11-14.04.2023
- Discussion at CAT and feedback to SAWP:	19-21.04.2023

5.2. Procedures discussed at SAWP – 1st reports, D40 JRs, LoIs

5.3. Finalisation of D70 procedures – feedback from the discussion meeting

5.4. Final Advice Letters for procedures finalised the previous month

6. Pre-Authorisation Activities

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Paediatric investigation plans

No items

6.2. ITF briefing meetings in the field of ATMPs

No items

6.3. Priority Medicines (PRIME) – Eligibility requests

6.3.1. Month 0 - Start of the procedure

Timetable for assessment:

Procedure start:	11-14.04.2023
SAWP recommendation:	12.05.2023
CAT recommendation:	17.05.2023
CHMP adoption of report and final recommendation:	25.05.2023

6.3.2. Month 1 – Discussion of eligibility

6.3.3. Month 2 – Recommendation of eligibility

6.3.4. Ongoing support

No items

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the CAT

7.1.1. CAT membership

Action: for information

7.1.2. Vote by proxy

Action: for information

7.1.3. CAT Strategic Review & Learning meeting (SRLM) under the Sweden presidency, 4 and 5 May 2023, Upsala (Sweden)

CAT: Lisbeth Barkholt, Maria Lüttgen

Scope: Topics for discussion at the upcoming SRLM

Action: for discussion

The final agenda of the upcoming SRLM was presented.

7.1.4. New timeschedule layout

CAT: Ilona Reischl

Scope: New layout of the timeschedule to capture all relevant information in a single location

Action: for discussion

EMA presented the new timeschedule layout, which aims to bring all relevant information together in a single excel file. CAT agreed to review it after a 4-month pilot.

CAT members to provide any comments or suggestions for further improvement to CAT Secretariat

7.2. Coordination with EMA Scientific Committees

None

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

7.3.1. PRIME implementation of 5-year review recommendations – 2023 pilot features and guidance updates

Scope: Summary of new features and their impact on CAT Rapporteurs

Action: for information

7.3.2. Joint EU GCP inspectors-clinical assessors virtual workshop, 26 June 2023

Scope: There will be a short presentation on the scope of the Joint EU GCP inspectors-clinical assessors virtual workshop organised by the subgroup of GCP inspectors and assessors working on embedding the outcome of GCP inspections into the benefit/risk assessment and modernisation of the inspection process. The presentation will also include a brief update on the deliverables of this subgroup.

Action: for information

CAT noted the information on the upcoming workshop. CAT members were asked to forward this information to the relevant colleagues in their agencies.

7.3.3. Re-organisation of Biologics Working Party (BWP)

Scope: BWP 3-year work plan and call for nominations

Action: for discussion

EMA informed CAT on the plan for Quality domain implementation. The end of the call for nominations for the BWP was noted (17.05.2023); the CAT Chair agreed to be part of the Quality Domain selection panel. Experts with quality (ATMP) expertise can be nominated by any CAT members for the Quality European Scientific Expert Community (ESEC).

7.4. Cooperation with the EU regulatory network

None

7.5. Cooperation with international regulators

7.5.1. ATMP cluster teleconference with US-FDA, Health Canada and PMDA (Japan)

CAT: Ilona Reischl

Scope: Feedback from the teleconference that was held on 13.04.2013

Action: for information

EMA provided feedback from the discussions at the last ATMP cluster TC.

7.6. CAT work plan

7.6.1. Guideline of quality, non-clinical and clinical requirements for investigational ATMPs in clinical trials

CAT topic leads: Ilona Reischl, Rune Kjekken, Claire Beuneu, Alessandro Aiuti

Scope: Comments received during the external consultation; discussion on the scope and content of the guideline

Action: for discussion

Ilona Reischl, on behalf of the drafting groups, informed CAT on the proposal for the structure of the guideline, the inclusion of a glossary and the potential extension of the scope to include guidance for novel products (e.g. genome editing). It will also be clarified in the guideline what will be the requirements for the clinical trial application versus development advice for the MAA.

The quality, non-clinical and clinical drafting groups will start reviewing the comments received during the public consultation (first drafting group meetings are scheduled for end of April/beginning of May). CAT will be kept informed of the progress of the drafting groups.

The feedback received from Finland and Sweden were briefly presented; CAT members can still provide observations to be taken into account by the drafting groups.

7.7. Planning and reporting

No items

7.8. Others

7.8.1. CAT stakeholder meeting 2023

CAT: Dariusz Sladowski, Ilona Reischl, Violaine Closson Carella, Carla Herberts

Scope: Topics proposed by the CAT stakeholders and plan of actions to prepare the agenda of the stakeholders meeting to take place on 16.05.2023

Action: for discussion

CAT agreed on the topics for discussion at the upcoming CAT stakeholder meeting. CAT members were appointed as speakers and/or moderators for the different topics. The stakeholder meeting will be a hybrid meeting, with part of the participant joining in person and part remotely (Webex).

7.8.2. Euroscan – International HealthTechScan (i-HTS)

CAT: Ilona Reischl

Scope: Feedback from the presentation by the CAT Chair on challenges in the field of ATMP in Europe at i-HTS Scientific meeting on ATMP4ALL – ‘How to raise awareness, equal access and trust in complex therapies in Europe?’

Action: for information

The CAT Chair presented the activities of EuroScan/i-HTS and the subgroup activities of ATMP4ALL, which are linked to health technology assessment (HTA)/reimbursement issues.

7.8.3. European Health and Digital Executive Agency (HaDEA)

CAT: Ilona Reischl

Scope: Update on HaDEA activities

Action: for information

The European Commission presented the role and activities of HaDEA. CAT members were encouraged to register themselves as experts to review project proposals.

8. Any other business

8.1. New Expert Management Tool

Scope: Presentation on the new Expert Management Tool to maintain a list of experts involved in medicines-related activities to collect their declarations of interests (eDoIs) and CVs

Action: for information

EMA provided a demonstration of the next expert management tool.

Date of next CAT meeting:

15-17 May 2023

9. List of participants

Including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 19-21 April 2023 meeting.

<u>Name</u>	<u>Role</u>	<u>Member State or affiliation</u>	<u>Outcome restriction following evaluation of e-DoI</u>	<u>Topics on agenda for which restrictions apply</u>
Ilona Reischl	Chair	Austria	No interests declared	
Silke Dorner	Member	Austria	No interests declared	
Corina Spreitzer	Alternate	Austria	No restrictions applicable to this meeting	
Claire Beuneu	Member	Belgium	No interests declared	

<u>Name</u>	<u>Role</u>	<u>Member State or affiliation</u>	<u>Outcome restriction following evaluation of e-DoI</u>	<u>Topics on agenda for which restrictions apply</u>
Rozalina Kulaksazova	Member	Bulgaria	No interests declared	
Evelina Shumkova	Alternate	Bulgaria	No interests declared	
Azra Selimovic	Member	Croatia	No interests declared	
Rafaella Pontou	Member	Cyprus	No interests declared	
Isavella Kyriakidou	Alternate	Cyprus	No interests declared	
Kristyna Rehorova Hradilkova	Alternate	Czechia	No interests declared	
Ebru Karakoc Madsen	Member	Denmark	No interests declared	
Bibi Fatima Syed Shah	Alternate	Denmark	No interests declared	
Toivo Maimets	Member	Estonia	No interests declared	
Pille Saalik	Alternate	Estonia	No interests declared	
Heli Suila	Member	Finland	No interests declared	
Maija Tarkkanen	Alternate	Finland	No interests declared	
Violaine Closson	Member	France	No interests declared	
Jean-Michel Race	Alternate	France	No interests declared	
Jan Mueller-Berghaus	Member (CHMP co-opted member)	Germany	No interests declared	
Egbert Flory	Alternate (to CHMP representative)	Germany	No interests declared	
Maria Gazouli	Member	Greece	No interests declared	
Angeliki Rompoti	Alternate	Greece	No interests declared	
Katalin Lengyel	Member	Hungary	No interests declared	
Maura O'Donovan	Member	Ireland	No interests declared	
Niamh Curran	Alternate	Ireland	No restrictions applicable to this meeting	
Concetta Quintarelli	Member	Italy	No interests declared	
Barbara Bonamassa	Alternate	Italy	No restrictions applicable to this meeting	

<u>Name</u>	<u>Role</u>	<u>Member State or affiliation</u>	<u>Outcome restriction following evaluation of e-DoI</u>	<u>Topics on agenda for which restrictions apply</u>
Raimondas Benetis	Alternate (to CHMP representative)	Lithuania	No interests declared	
Nancy De Bremaeker	Member	Luxembourg	No interests declared	
John J. Borg	Member (CHMP member)	Malta	No interests declared	
Anthony Samuel	Alternate (to CHMP representative)	Malta	No interests declared	
Carla Herberts	Member (Vice-Chair)	Netherlands	No interests declared	
Babs Fabriek	Alternate	Netherlands	No interests declared	
Rune Kjeklen	Member	Norway	No restrictions applicable to this meeting	
Dariusz Śladowski	Member	Poland	No restrictions applicable to this meeting	
Maria Isabel Borba Vieira	Alternate (to CHMP representative)	Portugal	No interests declared	
Silviu Istrate	Member	Romania	No interests declared	
Katarina Vavrová	Member	Slovakia	No interests declared	
Margareta Fogelová	Alternate	Slovakia	No interests declared	
Metoda Lipnik-Stangelj	Member	Slovenia	No interests declared	
Sol Ruiz	Member (CHMP co-opted member)	Spain	No interests declared	
Marcos Timón	Alternate (to CHMP representative)	Spain	No interests declared	
Lisbeth Barkholt	Member	Sweden	No interests declared	
Maria Luttgen	Alternate	Sweden	No participation in final deliberations and voting on:	
Alessandro Aiuti	Member	Clinicians' Representative	No restrictions applicable to this meeting	
Alessandra Renieri	Alternate	Clinicians' Representative	No restrictions applicable to this meeting	

<u>Name</u>	<u>Role</u>	<u>Member State or affiliation</u>	<u>Outcome restriction following evaluation of e-DoI</u>	<u>Topics on agenda for which restrictions apply</u>
Kerstin Sollerbrant	Member	Patients' Representative	No interests declared	
Kieran Breen	Member	Patients' Representative	No interests declared	
Hans Ovelgönne	Expert - via telephone*	Netherlands	No interests declared	
Torbjorn Callreus	Expert - via telephone*	Malta	No interests declared	
Christine Vaculik	Expert - via telephone*	Austria	No interests declared	
Rene Anour	Expert - via telephone*	Austria	No interests declared	
Bojana Divkovic	Expert - via telephone*	Austria	No interests declared	
Angelina Doriguzzi	Expert - via telephone*	Austria	No restrictions applicable to this meeting	
Florian Klinglmüller	Expert - via telephone*	Austria	No interests declared	
Christian Gartner	Expert - via telephone*	Austria	No interests declared	
Laura Rodríguez García	Expert - via telephone*	Spain	No interests declared	
Fernando Méndez	Expert - via telephone*	Spain	No interests declared	
Leire Aguado	Expert - via telephone*	Spain	No interests declared	
Macarena Rodríguez	Expert - via telephone*	Spain	No interests declared	
Concha Prieto	Expert - via telephone*	Spain	No interests declared	
David Ordonez	Expert - via telephone*	Spain	No interests declared	
Esther Rincon	Expert - via telephone*	Spain	No interests declared	
Jayne Crowe	Expert - via telephone*	Ireland	No interests declared	
Nathalie Morgensztejn	Expert - via telephone*	France	No interests declared	
Andreea Barbu	Expert - via telephone*	Sweden	No interests declared	
Peter Lohn	Expert - via telephone*	Sweden	No restrictions applicable to this meeting	
Tiina Holmberg	Expert - via telephone*	Finland	No interests declared	
Meeting run with support from relevant EMA staff				

10. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Abbreviations / Acronyms

AAV: Adeno-Associated Virus

AR: Assessment Report

ATMP: Advanced Therapy Medicinal Product

BWP: Biologics Working Party

CAT: Committee for Advanced Therapies

CHMP: Committee for Medicinal Product for Human Use

COMP: Committee for Orphan Medicinal Products

CTFG: Clinical Trial Facilitation Group

DG: Drafting Group

EC: European Commission

EU NTC: European Union Network Training Centre

ERA: Environmental Risk Assessment

FDA: Food and Drug Administration

FL: Final Letter

GCG: Guideline Consistency Group

GCP: Good Clinical Practice

GLP: Good Laboratory Practice

GMO: Genetically-modified organism

GMP: Good Manufacturing Practice

GTMP: Gene Therapy Medicinal Product

HTA: Health Technology Assessment Bodies

HSPC: Hematopoietic Stem and Progenitor Cells

ITF: Innovative Task Force

JR: Joint Report

LoOI: List of outstanding issues

LoQ: List of questions

MA: Marketing Authorisation

MAA: Marketing Authorisation Application

MAH: Marketing Authorisation Holder

MNAT: Multinational assessment team

MSC: Mesenchymal stem cells

PDCO: Paediatric Committee

PMDA: Pharmaceuticals and Medical Devices Agency (Japan)

PIP: Paediatric Investigation Plan

PL: Package leaflet

PRAC: Pharmacovigilance and Risk Assessment Committee #

PRIME: Priority Medicines

QRD: Quality review of documents

RMP: Risk Management Plan

RP: Reflection paper

RSI: Request for supplementary information

SAs: Scientific Advices

SAG-O: Scientific Advisory Group Oncology

SAWP: Scientific Advice Working Party

SR: Summary Report

SME: Small and medium size enterprises

SmPC: Summary of Products Characteristics

TT: Timetable


Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists Post-authorisation activities (section 2.11-2.13) and any ATMP related inspection requests (section 2.14).

New applications (sections 2.1. to 2.9.)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found [here](#).

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a **Day 120 list of questions** (section 2.4) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (**Ongoing evaluation procedures** (section 2.3)). Section 2.6 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

New applications (section 2.7.)

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

Withdrawal of applications (section 2.8.)

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.9.)

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

Companion diagnostics (section 2.10)

This section lists applications for initial and follow-on consultation of companion diagnostics.

Post-authorisation activities (section 2.11-2.13.)

Section 2.11 lists type II variations, including extension of indication applications and re-examination procedures for type II variations for which the applicant has requested re-examination of the opinion previously issued by the CHMP. Section 2.12 list extension application according to Annex I of Reg. 1234/2008 and section 2.13 includes all other post-authorisation activities concerning authorised ATMPs that are not covered elsewhere in the agenda such as post-authorisation measures, annual reassessments, 5-year renewals, supply shortages, qualify defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

GMP and GCP Inspections Issues (section 2.14.)

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Certification of ATMPs (section 3)

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found [here](#).

Scientific Recommendation on Classification of ATMPs (Section 4)

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found [here](#).

Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP.

Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found [here](#).

Pre-Authorisation (section 6)

Paediatric Investigation Plan (PIP)

This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

ITF Briefing meeting in the field of ATMPs

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found [here](#).

Priority Medicines (PRIME)

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

Organisational, regulatory and methodological matters (section 7)

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

Any other business (section 8)

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/